---
title: "U.S. stock night trading volatility: Jasper Therapeutics fell 3.93% in after-hours trading, with executive sell-offs and positive cooperation failing to mask market concerns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293558716.md"
description: "Jasper Therapeutics fell 3.93% in after-hours trading; BeiGene fell 0.11% in after-hours trading, with a transaction volume of USD 160,800; Moderna rose 0.26% in after-hours trading, with a transaction volume of USD 142,800; Zai Lab fell 0.34% in after-hours trading, with a transaction volume of USD 34,500"
datetime: "2026-07-23T04:46:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293558716.md)
  - [en](https://longbridge.com/en/news/293558716.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293558716.md)
---

# U.S. stock night trading volatility: Jasper Therapeutics fell 3.93% in after-hours trading, with executive sell-offs and positive cooperation failing to mask market concerns

**U.S. Stock Night Market Movements**

Jasper Therapeutics fell 3.93% in the night market. Based on recent key news:

1.  On July 22, Jasper Therapeutics Chief Operating Officer Matthew E. Ros reported 103,204 stock options at a price of $0.01 per share. This news may raise market attention on the company's internal equity distribution, leading to stock price fluctuations.
    
2.  On July 20, Jasper Therapeutics Director Patrick J. Crutcher reported 518,331 shares of common voting stock in Form 3. This information may attract investor attention to the company's governance structure, affecting the stock price.
    
3.  On July 20, the company announced a collaboration with Mirador to license KP-301 and KP-402 to accelerate the development of its product portfolio. This strategic move may be viewed as a positive signal by the market, but the short-term impact on the stock price remains unclear. The biotechnology industry has been volatile recently and requires attention.
    

**Stocks with High Trading Volume in the Industry**

BeiGene fell 0.11% in the night market. There has been no significant news recently; trading is active with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news

Moderna rose 0.26% in the night market. Based on recent key news:

1.  On July 20, the patent dispute between Moderna and CureVac attracted attention. CureVac accused Moderna of infringing its COVID-19 vaccine patents, leading to increased market concerns about Moderna's legal risks, affecting stock price fluctuations.
    
2.  On July 21, an antibody series conference involving Moderna attracted industry attention. The conference was supported by several leading companies in the industry, enhancing Moderna's influence in the biotechnology field and driving the stock price up.
    
3.  On July 22, Moderna's legal documents did not include agreement details, sparking market speculation. Investors are keeping an eye on the progress of the company's legal dispute with CureVac, affecting stock price trends. The biotechnology industry has been volatile recently and requires attention.
    

Zai Lab fell 0.34% in the night market. Based on recent news:

1.  On July 22, Zai Lab announced that it will release its Q2 2026 financial report on August 6. Market expectations and uncertainties before the financial report may lead to stock price fluctuations.
    
2.  On July 22, Zai Lab issued a notice providing investor relations and media contact information, indicating the company's active communication with the market, which may have some impact on the stock price. The market expects significant volatility before the financial report is released

### Related Stocks

- [JSPR.US](https://longbridge.com/en/quote/JSPR.US.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md)

## Related News & Research

- [Moderna CEO Stephane Bancel disposes of 499,246 shares for $9.56 million](https://longbridge.com/en/news/295273422.md)
- [Is Moderna (MRNA) Quietly Redefining Its Pipeline With Canada’s Bundibugyo Ebola Trial Green Light?](https://longbridge.com/en/news/295371859.md)
- [Arbutus Biopharma swings to Q2 loss as revenue falls; plans up to $230 mln shareholder returns](https://longbridge.com/en/news/295659838.md)
- [Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations](https://longbridge.com/en/news/295219760.md)
- [Moderna Stock (MRNA) Gains on U.S. Approval for New Flu Shot Type — Why This Matters](https://longbridge.com/en/news/295083162.md)